Best Oncology Companies in Seoul, South Korea
The 95 best Oncology companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Seoul
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases | $2.4B | 120 mo ago | 68 | 2014 | — | — | 32 patents Patents concentrated in chemistry & materials | — |
| 2 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 83 mo ago | 58 | 2016 | Dong Hoon Co-Founder & Co-CEO | — | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 3 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 54 mo ago | 24 | 2018 | — | — | — | — |
| 4 | Onconic Therapeutics Developer of therapeutics for the treatment of cancer and gastrointestinal diseases | $35M | 42 mo ago | 6 | 2020 | John Kim CEO | — | 114 patents Solid-form and salt optimization of heterocyclic anticancer small‑molecule therapeutics | — |
| 5 | Kanaph Developer of immunocytokine platform for treating cancer | $30M | 68 mo ago | 13 | 2019 | Byoung Lee CEO | PHPGSAPApache HTTP Server+8 | 2 patents Chain retention mechanisms for foldable bicycles preventing chain separation. | — |
| 6 | Tikaros Developer of immunotherapies for the treatment of cancer | $24M | 57 mo ago | — | 2018 | Kyungho Choi Co-Founder | — | — | — |
| 7 | Must Bio Developer of immunotherapeutics for cancer treatment | $24M | 3 mo ago | 18 | 2021 | Kim Seop CEO | — | — | — |
| 8 | Progen Developer of immunotherapies for immune diseases and cancer | $23M | 38 mo ago | — | 2000 | Jong Kim CEO | — | 73 patents Engineered Fc-fusion and bispecific therapeutic proteins, including IL-10 variants, for biologics. | — |
| 9 | Haim Bio Developer of anticancer drug that block metabolic pathways | $20M | 55 mo ago | — | 2011 | Hong Kim CEO | — | — | — |
| 10 | Eutilex Developing T cell-based therapeutics and antibodies for the treatment of cancer. | $18M | 114 mo ago | 103 | 2015 | Byoung Kwon Founder & CEO | PHPGSAPApache HTTP Server+6 | 191 patents Immuno‑oncology therapeutics: checkpoint antibodies, bispecifics, CAR‑T, and immune adjuvants | — |
| 11 | Uvic Steratics Developer of anti-cancer drugs based on Proteolysis Targeting Chimera 27Funding top 39%Talent bottom 49%Market bottom 39%Tech bottom 37% All 5 signals ▾Fundingtop 39% Talentbottom 49% Marketbottom 39% Techbottom 37% Globalbottom 37% Funding: Raised $17.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $18M | 17 mo ago | 41 | 2018 | Servo Optical CEO | Node.jsUbuntuReact+7 | — | — |
| 12 | Daan Biotherapeutics Developer of therapeutics for cancer treatment 19Moat top 38%Talent top 38%Patents top 43%Funding top 44% All 9 signals ▾Moattop 38% Talenttop 38% Patentstop 43% Fundingtop 44% Innovationbottom 47% Globalbottom 40% Growthbottom 35% Techbottom 31% Marketbottom 19% Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 19/100 | $17M | 28 mo ago | 4 | 2020 | J Han Founder | GnuboardMySQLPHP+18 | 8 patents Targeted cancer immunotherapy: anti-CEACAM5 antibodies and engineered T‑cell receptor therapies. | — |
| 13 | Oncocross Provider of AI-based drug discovery platform | $14M | 69 mo ago | 10 | 2015 | Jin Choi Co-Founder | PHPCodeIgniterBootstrap+14 | 132 patents AI-driven drug discovery and predictive therapeutics for cancer, kidney, and muscle diseases | 1 partnership |
| 14 | Neogen TC Developer of cell therapies for the treatment of cancer | $13M | 62 mo ago | — | 2020 | Heejin Lee CEO | — | — | — |
| 15 | Boostimmune Developer of therapeutics for cancer treatment | $13M | 48 mo ago | 5 | 2021 | Tadatsugu Taniguchi Co-Founder | — | 10 patents TCTP-based cancer biomarkers and therapeutic agents for immune‑modulating oncology. | — |
| 16 | NGeneBio In vitro cancer diagnostic products | $13M | 90 mo ago | 124 | 2015 | Min-Sik Kim Co-CEO | Microsoft ASP.NETGSAPCloudflare+8 | 46 patents Genetic diagnostics and personalized therapeutics via nucleic‑acid amplification and microbiome analysis | — |
| 17 | Olive Healthcare Provider of device for wellness and medical purpose | $10M | 77 mo ago | 24 | 2016 | Sung Han Founder & CEO | — | 60 patents Breast cancer diagnostic imaging devices (ultrasound/NIR) and body composition analysis tools. | — |
| 18 | Portrai Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification 22Patents top 37%Funding top 38%Innovation top 41%Global bottom 35% All 5 signals ▾Patentstop 37% Fundingtop 38% Innovationtop 41% Globalbottom 35% Marketbottom 22% Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 6 mo ago | 7 | 2021 | — | — | 29 patents Patents concentrated in computing, sensing & instrumentation | — |
| 19 | SN BioScience Developer of a nanoparticle-based drug-delivery system for cancer treatment | $4M | 89 mo ago | 24 | 2017 | — | — | 381 patents Vaccines and adjuvants for viral respiratory diseases, including mRNA and recombinant platforms | — |
| 20 | EPD Biotherapeutics Developer of targeted protein-degrading therapeutics for cancer and neurological disorders | $3M | 47 mo ago | 2 | 2021 | Seunghyun Lee Co-Founder | — | — | — |
| 21 | Novomics Developer of a molecular diagnosis system for cancer treatment | $3M | 114 mo ago | 5 | 2010 | Huh Yongmin CEO | — | 36 patents AI-based gastric cancer imaging analysis and predictive biomarkers for therapy response | — |
| 22 | ViroCure Developer of naturally occurring oncotropic viruses to treat cancers | $3M | 105 mo ago | 9 | 2016 | Dong Park CEO | — | 24 patents Reovirus-based viral vector vaccines for cancer immunotherapy and gastrointestinal inflammation | — |
Top 12 Oncology companies in Seoul
#1
Series C · Seoul, Seoul · founded 2021 · 18 employees$23.5Mraised▾
Developer of immunotherapeutics for cancer treatment. It offers multi-specific antibodies which include MB101, MB201, MB301, and MB401 for the treatment of multiple cancer. It offers multi-antibody platform technology to develop multiple antibodies.
- Mar 2026Series C$23.5M
- Series A—
- Series B—
#2
Series B · Seoul, Seoul · founded 2021 · 7 employees$9.9Mraised▾
Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification. The platform allow researchers to analyse the pathophysiology of diseases and discovers biomarkers, identify targets for new drugs, analyse the mode of action of drugs, and discover biomarkers.
- Dec 2025Series B$9.9M
#3
Series B · Seoul, Seoul · founded 2018 · 41 employees$17.6Mraised▾
Developer of anti-cancer drugs based on Proteolysis Targeting Chimera. It has an inhibitor technology that breaks down the target protein and expects the desired therapeutic efficacy by binding the target protein related to the disease targeted for degradation near the E3 ligase that can initiate the proteolysis system.
- Dec 2024Series B$17.6M
#4
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
#5
Series A · Seoul, Seoul · founded 2020 · 4 employees$17.2Mraised▾
Developer of therapeutics for cancer treatment. It offers immune-based cell therapies against lung cancer that expresses T Cell Receptors(TCR) based on natural killer cells and target EGFR mutations.
- Jan 2024Series A$17.2M
#6
Public · Seoul, Seoul · founded 2020 · 6 employees$34.9Mraised▾
Developer of therapeutics for the treatment of cancer and gastrointestinal diseases. The company's lead drug candidate is JPI-547, a dual inhibitory target anti-cancer drug candidate that inhibits both PARP and Tankyrase for pancreatic cancer. Also, it develops JP-1366 a proton pump inhibitor-based drug treatment for reflux esophagitis.
- Dec 2022Series B$19.9M
- Series A—
#7
Series B · Seoul, Seoul · founded 2000$22.8Mraised▾
Developer of immunotherapies for immune diseases and cancer. It offers a pipeline of drug candidates which include PG-102 for obesity, PG-208, PG-202, and others for oncology. It is based on NTIG (Neo Tri-ImmunoGlobulin) and Cyt-NTIG technology that overcomes the systemic side effects of cytokines through specific targeting.
- Apr 2023Series B$22.8M
#8
Series C · Seoul, Seoul · founded 2018 · 24 employees$40Mraised▾
Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases. The company's flagship product AST-021p that is an HSP90 peptide vaccine helps in the treatment of cancer. It has also developed AST-05X that is a GCN2 inhibitor that helps in treating cancer metabolism. Other products include AST-06X for CNS disorders, AST-301, AST-023 for cancer treatment, and more.
- Dec 2021Series C$22.7M
#9
Series B · Seoul, Seoul · founded 2016 · 58 employees$45.2Mraised▾
Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG).
- Jul 2019Series B$16M
- Nov 2018Series A$25M
- Apr 2018Seed$4.2M
#10
Public · Seoul, Seoul · founded 2019 · 13 employees$30Mraised▾
KANAPH Therapeutics is a developer of immunocytokine platform for T-cell based cancer treatment. The company uses the immunocytokine platform called TMEkine to activate the T-cells direct the cells to the tumor microenvironment to identify and kill the tumor cells. It is also developing small molecules and biologics against immuno-suppresive environment.
- Oct 2020Series B$21M
- Oct 2019Series A$6M
- Seed$2M
#11
Series C · Seoul, Seoul · founded 2018$24.4Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has CAR-T gene-modified cell therapies which include TC011, TC012 for lymphoma, TC002, TC003 for solid cancer, and TC007 for multiple myeloma. These therapies are based on clamping-based immunological synapse potentiating CAR technology.
- Aug 2021Series C$21.5M
#12
Series A · Seoul, Seoul · founded 2021 · 5 employees$13.2Mraised▾
Developer of therapeutics for cancer treatment. It offers multiple drug candidates that include antibody-drug conjugates, immune-stimulating antibody conjugates, and others that modulate the patient's immune cells and immune system.
- Jun 2022Series A$13.2M
- Aug 2021Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Seoul is moving
A read on the academic research around Oncology in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 105 papers.
Seoul National University and its hospital lead optimistic CAR-T and immunotherapy biomarker research, with 92% of 105 papers published recently, reflecting breakthrough-dominant, forward-looking oncology momentum.
- Seoul National University74
- Seoul National University Hospital24
- The Catholic University of Korea Seoul St. Mary\'s Hospital7
- Seoul National University Bundang Hospital7
- Seoul St. Mary\'s Hospital3
- Tumor microenvironment1→16
- Immune system1→12
- Stromal cell1→3
- Tumor microenvironment2→27
- Cancer research3→19
- Cytotoxic T cell1→4
- Cancer2→5
- Tumor microenvironment3
- Cancer3
- Immunotherapy2
- Immune system1
- Cancer immunotherapy1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.